Latest news

• Cosentyx, Entresto drive topline growth for Novartis in Q4

  Novartis also highlighted success in its approvals from 2019: this included Zolgensma, breast cancer treatment Piqray (alpelisib), multiple sclerosis drug Mayzent (siponimod), wet age-related macular degeneration treatment Beovu (brolucizumab) and

• Novartis highlights emerging assets and late-stage pipeline at R&D day

  It also has plans to expand wet AMD therapy  Beovu(brolucizumab-dbll) and HER-2 breast cancer treatments  Piqray (alpelisib) and  Kisqali(ribociclib) into additional indications to help drive growth.

• Biogen takes on Lucentis, Eylea biosimilars from Samsung joint venture

  Novartis recently claimed a US approval for a follow-up VEGF inhibitor  Beovu (brolucizumab), which requires fewer injections into the eye, in an attempt to protect its AMD franchise ahead of

• Novartis bags US okay for Lucentis follow-up Beovu in wet AMD

  Head-to-head trial with rival Eylea could boost sales. The FDA has approved Novartis’ new VEGF inhibitor Beovu as a new treatment option for patients with the wet form of ... That compares to four to eight week dosing with Eylea, and every month with

• After Lucentis setback, Novartis trumpets data on follow-up drug

  Next gen eye treatment offers less frequent dosing